Zobrazeno 1 - 10
of 187
pro vyhledávání: '"Pedro Jares"'
Autor:
Elena María Fernández-Garnacho, Ferran Nadeu, Silvia Martín, Pablo Mozas, Andrea Rivero, Julio Delgado, Eva Giné, Armando López-Guillermo, Martí Duran-Ferrer, Itziar Salaverria, Cristina López, Sílvia Beà, Santiago Demajo, Pedro Jares, Xose S. Puente, José Ignacio Martín-Subero, Elías Campo, Lluís Hernández
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract MALAT1 long non-coding RNA has oncogenic roles but has been poorly studied in indolent B-cell neoplasms. Here, MALAT1 expression was analyzed using RNA-seq, microarrays or qRT-PCR in primary samples from clinico-biological subtypes of chroni
Externí odkaz:
https://doaj.org/article/ae1ddb4b3027446b8ee9e79f800947ba
Autor:
Teresa Gorria, Carme Crous, Estela Pineda, Ainhoa Hernandez, Marta Domenech, Carolina Sanz, Pedro Jares, Ana María Muñoz-Mármol, Oriol Arpí-Llucía, Bárbara Melendez, Marta Gut, Anna Esteve, Anna Esteve-Codina, Genis Parra, Francesc Alameda, Cristina Carrato, Iban Aldecoa, Mar Mallo, Nuria de la Iglesia, Carmen Balana
Publikováno v:
Cancers, Vol 16, Iss 4, p 735 (2024)
The aim of this study was to determine how TERTp mutations impact glioblastoma prognosis. Materials and Methods: TERTp mutations were assessed in a retrospective cohort of 258 uniformly treated glioblastoma patients. RNA-sequencing and whole exome se
Externí odkaz:
https://doaj.org/article/d939346e85064523b1c60d72c208c065
Autor:
Irene López-Oreja, Mónica López-Guerra, Juan Correa, Pablo Mozas, Ana Muntañola, Luz Muñoz, Ana-Camino Salgado, Sílvia Ruiz-Gaspà, Dolors Costa, Sílvia Beà, Pedro Jares, Elías Campo, Dolors Colomer, Ferran Nadeu
Publikováno v:
HemaSphere, Vol 7, Iss 10, p e962 (2023)
Externí odkaz:
https://doaj.org/article/fe48211339c6483a89722b872413d1e4
Autor:
Francesco Schettini, Elia Seguí, Benedetta Conte, Esther Sanfeliu, Blanca Gonzalez-Farre, Pedro Jares, Sergi Vidal-Sicart, Sergi Ganau, Isaac Cebrecos, Fara Brasó-Maristany, Montserrat Muñoz, Aleix Prat, Maria Vidal
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundCDK4/6 inhibitors (CDKi), namely, palbociclib, ribociclib, and abemaciclib, combined with either an aromatase inhibitor (AI) or fulvestrant are the standard first/second line for hormone receptor-positive(HR+)/HER2-negative(neg) metastatic
Externí odkaz:
https://doaj.org/article/4c555861a9c24c34a6e369dd882b1e25
Autor:
Isabel Trias, Adela Saco, Lorena Marimon, Ricardo López del Campo, Carolina Manzotti, Oriol Ordi, Marta del Pino, Francisco M. Pérez, Naiara Vega, Silvia Alós, Antonio Martínez, Leonardo Rodriguez-Carunchio, Oscar Reig, Pedro Jares, Cristina Teixido, Tarek Ajami, Juan Manuel Corral-Molina, Ferran Algaba, María J. Ribal, Inmaculada Ribera-Cortada, Natalia Rakislova
Publikováno v:
Cancers, Vol 15, Iss 10, p 2719 (2023)
p53 immunohistochemistry (IHC) has been proposed as a surrogate for TP53 mutations in penile squamous cell carcinomas (PSCC). We aimed to evaluate the performance of a pattern-based evaluation of p53 IHC in PSCC. Human papilloma virus (HPV) DNA testi
Externí odkaz:
https://doaj.org/article/2188d1a36e6e45239cabaf5c5e09c677
Autor:
Paola Castillo, Marta Marginet, Pedro Jares, Mireia García, Elena Gonzalvo, Ana Arance, Adriana García, Llucia Alos, Cristina Teixido
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 1, Iss 2, Pp 101-108 (2020)
Aim: Single biomarker diagnostic test of BRAFV600 locus in metastatic melanoma is mandatory for treatment decision; however, multiple-gene based techniques, such as targeted next-generation sequencing (NGS) are being used to maximize the number of pa
Externí odkaz:
https://doaj.org/article/050fac3f16f04fb281431168feb73533
Autor:
Aleix Prat, Valentina Guarneri, Tomás Pascual, Fara Brasó-Maristany, Esther Sanfeliu, Laia Paré, Francesco Schettini, Débora Martínez, Pedro Jares, Gaia Griguolo, Maria Vittoria Dieci, Javier Cortés, Antonio Llombart-Cussac, Benedetta Conte, Mercedes Marín-Aguilera, Nuria Chic, Joan Anton Puig-Butillé, Antonio Martínez, Patricia Galván, Yi-Hsuan Tsai, Blanca González-Farré, Aurea Mira, Ana Vivancos, Patricia Villagrasa, Joel S. Parker, Pierfranco Conte, Charles M. Perou
Publikováno v:
EBioMedicine, Vol 75, Iss , Pp 103801- (2022)
Summary: Background: Both clinical and genomic data independently predict survival and treatment response in early-stage HER2-positive breast cancer. Here we present the development and validation of a new HER2DX risk score, and a new HER2DX patholog
Externí odkaz:
https://doaj.org/article/0fd537b853eb4d46994417b689144024
Autor:
Sara Lahoz, Adela Rodríguez, Laia Fernández, Teresa Gorría, Reinaldo Moreno, Francis Esposito, Helena Oliveres, Santiago Albiol, Tamara Saurí, David Pesantez, Gisela Riu, Miriam Cuatrecasas, Pedro Jares, Leire Pedrosa, Estela Pineda, Antonio Postigo, Antoni Castells, Aleix Prat, Joan Maurel, Jordi Camps
Publikováno v:
Cancers, Vol 14, Iss 23, p 5921 (2022)
Next–generation sequencing (NGS) provides a molecular rationale to inform prognostic stratification and to guide personalized treatment in cancer patients. Here, we determined the prognostic and predictive value of actionable mutated genes in metas
Externí odkaz:
https://doaj.org/article/a0b928aefc1849e083f5aa2177736586
Autor:
Fara Brasó-Maristany, Miriam Sansó, Nuria Chic, Débora Martínez, Blanca González-Farré, Esther Sanfeliu, Lucio Ghiglione, Esther Carcelero, Javier Garcia-Corbacho, Marcelo Sánchez, Dolors Soy, Pedro Jares, Vicente Peg, Cristina Saura, Montserrat Muñoz, Aleix Prat, Ana Vivancos
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The immune checkpoint inhibitor atezolizumab is approved for PD-L1-positive triple-negative breast cancer (TNBC). However, no activity of atezolizumab in PD-L1-negative TNBC has been reported to date. Here, we present the case study of a woman with T
Externí odkaz:
https://doaj.org/article/ed4b45258e414194b8958445070c4092
Autor:
Inmaculada Ribera-Cortada, José Guerrero-Pineda, Isabel Trias, Luis Veloza, Adriana Garcia, Lorena Marimon, Sherley Diaz-Mercedes, José Ramon Alamo, Maria Teresa Rodrigo-Calvo, Naiara Vega, Ricardo López del Campo, Rafael Parra-Medina, Tarek Ajami, Antonio Martínez, Oscar Reig, Maria J. Ribal, Juan Manuel Corral-Molina, Pedro Jares, Jaume Ordi, Natalia Rakislova
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 1, p 251 (2021)
Penile squamous cell carcinoma (PSCC) is a rare but aggressive neoplasm with dual pathogenesis (human papillomavirus (HPV)-associated and HPV-independent). The development of targeted treatment is hindered by poor knowledge of the molecular landscape
Externí odkaz:
https://doaj.org/article/46bba1527d9d4e0b83c5af488d824b99